FDA approves the first once-monthly subcutaneous olanzapine for schizophrenia
For your practiceNo loading dose, no oral overlap and no post-injection monitoring window: the usual barriers to a long-acting injectable, removed.
AJMC · Oct 9
For your practiceNo loading dose, no oral overlap and no post-injection monitoring window: the usual barriers to a long-acting injectable, removed.
AJMC · Oct 9
Remibrutinib becomes the first approved treatment for symptomatic dermographism AJMC · Oct 7
Atezolizumab plus chemotherapy approved for stage III dMMR colon cancer FDA · Oct 8
Tucatinib added to trastuzumab and pertuzumab for HER2-positive maintenance FDA · Oct 7
Pirtobrutinib approved for previously untreated CLL/SLL AJMC · Oct 2
Gabapentin for chronic low back pain linked to higher 10-year dementia risk Reg Anesth Pain Med
Oral icotrokinra holds skin clearance at two years in plaque psoriasis HCPLive · Oct 10
Nemolizumab sustains itch relief for up to three years in AD and prurigo nodularis HCPLive · Oct 10
FDA posts its April–June 2026 potential safety signals from adverse event reports FDA · Sep 30
Kybella labeling updated with warnings on reactions from unapproved use FDA · Sep 15
Boxed warning added to Injectafer for risk of low phosphate FDA · Sep 1
Medicare open enrollment opens Thursday; patients on Part D should re-check formularies CMS · Sep 28
Negotiated Medicare prices for 15 more drugs, including semaglutide, start January 1 Becker’s
Join the network and never miss what never gets posted: the dinner, the invitation to speak, the paid advisory board. Free for every verified clinician.
Join free: the Monday edition, plus the invitations you won’t hear about anywhere else.Join the network ›Before you write the script.
Every month: the coverage changes for what you prescribe, by plan and by state.
Clear clinical perspective on what you treat.
AI answers the question you ask. Rounds brings the ones you didn’t know to ask, chosen by what you treat, in 90 seconds each.
A colleague who’s been there, on camera.
The case, the data and the access — in your inbox and on your screen.
Twenty minutes in your office, or on screen when that’s easier.
On the part AI and the PI stop short of.
A clinician comes to your office. Lunch is on us.
Thirty minutes with a clinician who treats what you treat.
Every one ends with how peers are getting it approved.An evening with clinicians who treat what you treat.
Seats near you, held first for clinicians who haven’t had one.
Every one ends with how peers are getting it approved.Your peers want to hear from you. Get paid for your time.
Dinner talks, lunch programs and live sessions in your therapy area — with an honorarium for every one you accept.
NPs, PAs, MDs and DOs — from the leaders of America’s biggest institutions to the best-known voice in town. You choose every engagement.
Samples, starter kits and savings for what you treat.
Offered in the therapy areas you treat — including the ones you won’t find on a website.
Market research, advisory boards and clinical trials.
Get paid for what you know. Tell us what you’d consider, and when a paid survey, board or study site opens in your area, we put your name forward.
Your first three years. The works.
Manufacturers build an extraordinary amount for prescribers. You’ve moved three times since licensure — we make sure it still finds you.
Picked for your specialty, your state and where you are in your first three years.
Open to every licensed prescriber. Tell us your licensure year and we’ll start where you are.
No app, no portal, no schedule to keep. When there’s something worth your time near you, you hear from us — and it’s always yours to pass on.
verified clinicians, 10+ years.
It began as a grassroots network for nurse practitioners and physician assistants. Today it’s a bridge between prescribers and the best of life sciences, on clinicians’ terms.
By the best names in life sciences. The sponsor is always named.
A clinician or medical expert stands behind every session.
One goal: helping you help your patients.
The Monday news, the dinner, the invitation to speak, the paid opportunity. From the Prescriber News Network.